Search in:

Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 1

Submit an article Journal homepage

672

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Pegasparaginase: where do we stand?

Amer Zeidan Rochester General Hospital, General Medicine Unit, Division of Hospital Medicine, Rochester, New York, USA

, MD,

Eunice S Wang Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Streets, Buffalo, 14263, New York, USA +1 716 845 8447; +1 716 845 2343; [email protected]; State University of New York at Buffalo, Department of Medicine, Buffalo, New York, USA

, MD &

Meir Wetzler Roswell Park Cancer Institute, Department of Medicine, Leukemia Section, Elm and Carlton Streets, Buffalo, 14263, New York, USA +1 716 845 8447; +1 716 845 2343; [email protected]

, MD

Pages 111-119 | Published online: 19 Nov 2008

Cite this article
https://doi.org/10.1517/14712590802586058

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Mashburn LT, Wriston JC Jr. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:450-2
PubMed Web of Science ®Google Scholar
Park YK, Abuchowski A, Davis S, et al. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. Anticancer Res 1981;1:373-6
PubMed Web of Science ®Google Scholar
Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:S3-8
PubMed Web of Science ®Google Scholar
Keating MJ, Holmes R, Lerner S, et al. L-asparaginase and PEG asparaginase –past, present, and future. Leuk Lymphoma 1993;(10 Suppl):153-7
PubMedGoogle Scholar
Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005;44:367-93
PubMed Web of Science ®Google Scholar
Apostolidou E, Swords R, Alvarado Y, et al. Treatment of acute lymphoblastic leukaemia: a new era. Drugs 2007;67:2153-71
PubMed Web of Science ®Google Scholar
Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia – asparagine synthetase. Biochem Pharmacol 1969;18:2578-80
PubMed Web of Science ®Google Scholar
Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281:1028-34
PubMed Web of Science ®Google Scholar
Haskell CM, Canellos GP. Asparaginase and leukaemia. Lancet 1969;1:626
PubMed Web of Science ®Google Scholar
Haskell CM, Canellos GP, Cooney DA, et al. Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med 1970;75:763-70
PubMedGoogle Scholar
Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol 1970;10:421-40
PubMedGoogle Scholar
Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893-901
PubMed Web of Science ®Google Scholar
Nandy P, Periclou AP, Avramis VI. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. Anticancer Res 1998;18:727-37
PubMed Web of Science ®Google Scholar
Fu CH, Martin-Aragon S, Weinberg KI, et al. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Cancer Chemother Pharmacol 2001;48:123-33
PubMed Web of Science ®Google Scholar
Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744-50
PubMed Web of Science ®Google Scholar
Miller HK, Balis ME. Glutaminase activity of L-asparagine amidohydrolase. Biochem Pharmacol 1969;18:2225-32
PubMed Web of Science ®Google Scholar
Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217-26
PubMed Web of Science ®Google Scholar
Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004;24:1121-5
PubMed Web of Science ®Google Scholar
Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-94
PubMed Web of Science ®Google Scholar
Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986;14:349-52
PubMed Web of Science ®Google Scholar
Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6
PubMed Web of Science ®Google Scholar
Holle LM. Pegaspargase: an alternative? Ann Pharmacother 1997;31:616-24
PubMed Web of Science ®Google Scholar
Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-11
PubMed Web of Science ®Google Scholar
Woo MH, Hak LJ, Storm MC, et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:1568-73
PubMed Web of Science ®Google Scholar
Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-8
PubMed Web of Science ®Google Scholar
Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24-31
PubMed Web of Science ®Google Scholar
Jayaram HN, Cooney DA, Jayaram S, et al. A simple and rapid method for the estimation of L-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods. Anal Biochem 1974;59:327-46
PubMed Web of Science ®Google Scholar
Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709-15
PubMed Web of Science ®Google Scholar
Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-50
PubMed Web of Science ®Google Scholar
Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-41
PubMed Web of Science ®Google Scholar
Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9-13
PubMedGoogle Scholar
Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-83
PubMed Web of Science ®Google Scholar
Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33
PubMed Web of Science ®Google Scholar
Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-9
PubMed Web of Science ®Google Scholar
Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123:836-41
PubMed Web of Science ®Google Scholar
Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175-86
PubMedGoogle Scholar
Wada H, Imamura I, Sako M, et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 1990;613:95-108
PubMed Web of Science ®Google Scholar
Muss HB, Spell N, Scudiery D, et al. A Phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990;8:125-30
PubMed Web of Science ®Google Scholar
Kawashima K, Takeshima H, Higashi Y, et al. High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies. Leuk Res 1991;15:525-30
PubMed Web of Science ®Google Scholar
Agrawal NR, Bukowski RM, Rybicki LA, et al. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 2003;98:94-9
PubMed Web of Science ®Google Scholar
Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12:991-8
PubMed Web of Science ®Google Scholar
Ettinger LJ, Kurtzberg J, Voute PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-81
PubMed Web of Science ®Google Scholar
Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000;110:379-84
PubMed Web of Science ®Google Scholar
Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-302
PubMed Web of Science ®Google Scholar
Douer D, Cohen LJ, Periclou LA, et al. Peg-L-asparaginase (PEG-ASP): Pharmacokinetics (PK) and clinical response in newly diagnosed adults with acute lymphoblastic leukemia (ALL) treated with multiagent chemotherapy. Blood 1997;90(Suppl 1):334a
Google Scholar
Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-7
PubMed Web of Science ®Google Scholar
Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8:1977-84
PubMed Web of Science ®Google Scholar
Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-(1962) J Pediatr Hematol Oncol 2002;24:175-81
PubMed Web of Science ®Google Scholar
Peters BG, Goeckner BJ, Ponzillo JJ, et al. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment Formulary 1995;30:388-93
PubMed Web of Science ®Google Scholar
Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19:458-77
PubMed Web of Science ®Google Scholar
Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-8
PubMed Web of Science ®Google Scholar
Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-5
PubMed Web of Science ®Google Scholar
Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-32
PubMed Web of Science ®Google Scholar
Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 2007;29:627-32
PubMed Web of Science ®Google Scholar
Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57
PubMed Web of Science ®Google Scholar
Williams DA. A new mechanism of leukemia drug resistance? N Engl J Med 2007;357:77-8
PubMed Web of Science ®Google Scholar
Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297-305
PubMed Web of Science ®Google Scholar
Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99-104
PubMedGoogle Scholar
Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli. L-asparaginase in man. Cancer 1970;25:253-78
PubMedGoogle Scholar
Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-5
PubMed Web of Science ®Google Scholar
Su N, Pan YX, Zhou M, et al. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2008;50:274-9
PubMed Web of Science ®Google Scholar
Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85:751-6
PubMed Web of Science ®Google Scholar
Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-9
PubMed Web of Science ®Google Scholar
Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003;101:2743-7
PubMed Web of Science ®Google Scholar
Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008;22:1665-79
PubMed Web of Science ®Google Scholar
Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8
PubMed Web of Science ®Google Scholar
Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091-7
PubMed Web of Science ®Google Scholar
Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932-9
PubMed Web of Science ®Google Scholar
Tardito S, Uggeri J, Bozzetti C, et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 2007;60:751-8
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pegasparaginase: where do we stand?

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pegasparaginase: where do we stand?

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date